Performing immunohistochemical stain for c-MYC expression is important for prognosis in diffuse large B-cell lymphoma (DLBCL), as DLBCLs with expression of both c-MYC and B-cell lymphoma 2 protein (BCL2) (so-called “double-expressor” lymphoma) have worse clinical outcome than other DLBCL, NOS treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) [49,50]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.